熱門詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
熱門詞： 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
Tau Therapeutics 美國(guó)Tau Therapeutics
研發(fā)的T型鈣通道阻滯劑米貝拉地爾（mibefradil）用于實(shí)體腫瘤的治療。
Tau Therapeutics is developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. The company’s approach, called Interlaced Therapy?, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.
Tau’s first product, mibefradil, has been used extensively in humans and its safety profile is well known. Mibefradil is now entering clinical trials for brain cancer with support from the NCI.
Tau Therapeutics is a private company based in Charlottesville, VA.
知識(shí)產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請(qǐng)聯(lián)系：400-006-7520 ，我們會(huì)在第一時(shí)間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號(hào)
